T.Y. and Y.U. contributed equally to this work.
Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study
Article first published online: 3 MAR 2011
© 2011 Blackwell Publishing Limited
Volume 58, Issue 4, pages 608–616, March 2011
How to Cite
Yoshioka, T., Umekita, Y., Ohi, Y., Souda, M., Sagara, Y., Sagara, Y., Sagara, Y., Rai, Y. and Tanimoto, A. (2011), Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study. Histopathology, 58: 608–616. doi: 10.1111/j.1365-2559.2011.03781.x
- Issue published online: 17 MAR 2011
- Article first published online: 3 MAR 2011
- Date of submission 27 January 2010 Accepted for publication 25 May 2010
- breast cancer;
Yoshioka T, Umekita Y, Ohi Y, Souda M, Sagara Y, Sagara Y, Sagara Y, Rai Y & Tanimoto A (2011) Histopathology58, 608–616 Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study
Aims: Aldehyde dehydrogenase 1 (ALDH1) has been identified as a reliable marker of breast cancer stem cells. The aim was to determine the prognostic significance of ALDH1 expression in a long-term follow-up study.
Methods and results: Immunohistochemical analyses were performed on 257 invasive ductal carcinomas (IDCs), 109 matched lymph node metastases and 190 ductal carcinomas in situ (DCISs), using paraffin-embedded sections. ALDH1 expression was found in 26% of IDCs, and correlated with larger tumour size (P = 0.007), high histological grade (P < 0.001), HER2 overexpression (P < 0.001) and negative hormone receptor status (P < 0.001). ALDH1 expression was observed in 14% of DCISs but was not correlated with any clinicopathological parameter. The IDC patients were followed up for 7–190 months (median: 120 months), and groups with ALDH1 expression had shorter relapse-free survival (P = 0.0013) and overall survival (OS) (P = 0.0005) by log-rank test. By Cox’s multivariate analysis, it had a weak effect on OS (P = 0.047), and its most significant effect on OS was observed in node-positive groups (P = 0.013). No significant differences in OS stratified by ALDH1 expression status in lymph node metastases were noted.
Conclusions: ALDH1 expression in primary cancer is an independent prognostic factor in node-positive breast cancer patients.